Caxton Associates (New York)’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$1.6M Sell
60,414
-16,211
-21% -$440K 0.05% 131
2024
Q3
$2.22M Buy
76,625
+50,232
+190% +$1.47M 0.08% 106
2024
Q2
$738K Buy
+26,393
New +$727K 0.03% 281
2023
Q4
Sell
-45,018
Closed -$1.49M 522
2023
Q3
$1.49M Buy
45,018
+3,043
+7% +$108K 0.21% 86
2023
Q2
$1.54M Buy
+41,975
New +$1.63M 0.23% 96
2023
Q1
Sell
-2,874,544
Closed -$147M 601
2022
Q4
$147M Buy
2,874,544
+8,794
+0.3% +$422K 9.83% 3
2022
Q3
$125M Sell
2,865,750
-21,580
-0.7% -$1.05M 16.71% 1
2022
Q2
$151M Sell
2,887,330
-1,932
-0.1% -$98.5K 14.71% 1
2022
Q1
$150M Buy
2,889,262
+498,845
+21% +$25.9M 12.17% 3
2021
Q4
$141M Buy
2,390,417
+910,417
+62% +$45.1M 14.37% 1
2021
Q3
$63.7M Buy
+1,480,000
New +$65.6M 7.03% 4
2019
Q4
Sell
-13,885
Closed -$473K 515
2019
Q3
$473K Buy
+13,885
New +$505K 0.09% 142
2018
Q3
Sell
-10,654
Closed -$367K 511
2018
Q2
$367K Buy
+10,654
New +$364K 0.02% 286
2014
Q2
Sell
-105,400
Closed -$3.21M 235
2014
Q1
$3.21M Buy
+105,400
New +$3.14M 0.2% 91

Other funds holding PFE

Caxton Associates (New York)'s PFE Position: Q4 2024 in Review

Caxton Associates (New York) reduced its Pfizer (PFE) stake by 21% in Q4 2024, selling an estimated $440K and leaving 60,414 shares worth $1.6M. The position accounts for 0.05% of the portfolio, ranked #131.

Caxton Associates (New York) first reported a position in PFE in Q1 2014 and has held it in 14 quarters since. The position peaked at $151M in Q2 2022. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

  • Caxton Associates (New York) held 60,414 shares of Pfizer worth $1.6M as of Q4 2024.
  • Caxton Associates (New York) sold 16,211 Pfizer shares in Q4 2024, an estimated $440K.
  • Pfizer made up 0.05% of Caxton Associates (New York)'s portfolio in Q4 2024, its #131 holding.
  • Caxton Associates (New York) first reported a position in Pfizer in Q1 2014 and has held it in 14 quarters since.
  • Caxton Associates (New York)'s Pfizer position peaked at $151M in Q2 2022.
  • 2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.